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Dihydropyrimidine dehydrogenase (DPD, EC 1.3.1.2) is the initial
and rate-limiting enzyme in the catabolism of the pyrimidine
bases, and it catalyses the reduction of thymine and uracil to 5,6-
dihydrothymine and 5,6-dihydrouracil, respectively. In children,
the deficiency of DPD is often accompanied by a neurological
disorder, but a considerable variation in the clinical presentation
among these patients has been reported (Van Gennip et al, 1994,
1997). In these patients, a large accumulation of uracil and
thymine has been detected in urine, blood and in cerebrospinal
fluid (Van Gennip et al, 1993, 1994, 1997). Recently, we have
identified several types of mutations in the DPD gene underlying
this deficiency in these patients with no detectable activity of DPD
(Meinsma et al, 1995; Vreken et al, 1996, 1997a, 1997b).
DPD is also responsible for the breakdown of the widely used
antineoplastic agent 5-fluorouracil (5-FU), thereby limiting the
efficacy of the therapy. 5-FU is one of the few drugs that shows
some anti-tumour activity against various otherwise untreatable
tumours, including carcinomas of the gastrointestinal tract, breast,
ovary and skin. Furthermore, 5-FU is one of the few drugs for
which an, albeit limited, clinical effect has been shown when
applied as a single agent during the treatment of advanced
colorectal cancer. To exert its cytotoxic effect against cancer, 5-FU
must first be anabolized to the nucleotide level. Although the cyto-
toxic effects of 5FU are probably directly mediated by the anabolic
pathways, the catabolic route plays a significant role because more
than 80% of the administered 5-FU is catabolized by DPD (Heggie
et al, 1987). Indeed, inhibitors of DPD have been shown to poten-
tiate the effect of 5-FU in vitro and in vivo (Daher et al, 1991;
Spector et al, 1993; Baker et al, 1996). Furthermore, a correlation
has been observed between the pretreatment activity of DPD in
peripheral blood mononuclear cells (PBM cells) and the systemic
clearance of 5-FU in cancer patients (Fleming et al, 1992; Etienne
et al, 1994). However, a large interpatient and intrapatient vari-
ability in the activity of DPD was observed (Fleming et al, 1992;
Etienne et al, 1994).
The important role of DPD in the chemotherapy with 5-FU has
also been shown in cancer patients with a complete or near-
complete deficiency of this enzyme. These patients suffered from
severe toxicity, including death, after 5-FU chemotherapy
(Tuchman et al, 1985; Diasio et al, 1988; Harris et al, 1991;
Fleming et al, 1993; Houyau et al, 1993; Lu et al, 1993; Lyss et al,
1993; St￿phan et al, 1995; Beuzeboc et al, 1996; Takamoto et al,
1996; Van Kuilenburg et al, 1997a, 1998a). A clinical pharmaco-
logical study of one of these patients with a complete deficiency of
DPD demonstrated a minimal catabolism of 5-FU, with a tenfold
longer 5FU half-life compared with patients with a normal activity
of DPD (Diasio et al, 1988). Recently, we described a patient with
a low activity of DPD experiencing severe toxicity after 5FU
chemotherapy (Van Kuilenburg et al, 1997a, 1998a). The occur-
rence of hyperpigmentation and cardiotoxicity in this patient
might be related to increased 5FU levels due to a decreased
activity of DPD. Interestingly, this patient proved to be heterozy-
gous for a G®A point mutation in an invariant GT splice donor
sequence of the gene coding for DPD, leading to faulty splicing
(Van Kuilenburg et al 1997a, 1998a). Because the frequency of
heterozygotes in the normal population has been estimated to be as
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Amsterdam, The Netherlandshigh as 3% (Fernandez-Salguero et al, 1995), such patients might
be at risk of developing severe toxicity after the administration of
5FU. Considering the frequent use of 5FU in the treatment of
cancer patients and the severe 5FU-related toxicities in patients
with a low activity of DPD, the analysis of the DPD activity before
the start of the treatment with 5FU has been advocated (Lu et al,
1993; Van Kuilenburg et al, 1997a).
The activity of DPD is present exclusively in the cytosol (Van
Kuilenburg et al, 1997b, 1998b) and can be detected in a variety of
human tissues, with the highest activity being found in liver and
lymphocytes (Naguib et al, 1985; Ho et al, 1986). To identify
patients suffering from a complete or partial DPD deficiency, PBM
cells are frequently used. So far, it is not known whether the
activity of DPD is also present in other blood cell types. In this
study, we demonstrate that the highest activity of DPD is present in
monocytes, and that a profound correlation exists between the
percentage of monocytes in PBM cells and the activity of DPD,
thus, hindering the detection of patients with a partial DPD
deficiency.
MATERIALS AND METHODS
Materials
[2-14C]Thymine was obtained from Biotrend (K￿ln, Germany).
Lymphopaque was obtained from Nyegaard & Co. (Oslo,
Norway). Fetal calf serum (FCS) and RPMI-1640 medium with
20 mM Hepes were obtained from Flow Laboratories (Irvine, UK);
LeucoSep tubes were supplied by Greiner (Frickenhausen,
Germany). All other chemicals were of analytical grade.
Patients
Informed consent was obtained from all patients and healthy
volunteers before entry into the study. Thirteen patients with
cancer entered the study, consisting of eight men and five women;
median age was 64 years (range 41—88). Five patients with
metastatic colorectal cancer were treated with continuous infusion
of 5-FU; four patients received a dose of 300 mg m—2 day—1 and one
patient received a dose of 450 mg m—2 day—1. Four patients with
metastatic renal cell carcinoma were treated with a circadian
modulated continuous infusion of fluorodeoxyuridine, and they
received doses varying from 0.175 to 0.325 mg kg—1 day—1. Before
treatment, a venous access device (Port-a-Cath, Pharmacia Deltec,
St. Paul, USA) was implanted, and the chemotherapy was deliv-
ered by an ambulatory portable infusion pump (Pharmacia Cadd-
Plus, Pharmacia Deltec). Treatment was scheduled for 14 days
every 4 weeks. Blood samples were taken at day 7, halfway
through the chemotherapy course. Four patients with cancer local-
ization in the digestive tract and bladder were treated with other
types of chemotherapy and/or radiotherapy. Twenty-two healthy
volunteers entered the study. In all cases, blood samples were
collected between 08.00 and 10.00 h to minimize the influence of
a possible circadian rhythm of the activity of DPD.
Isolation of human peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBM cells) were isolated
from 15 ml of EDTA-anticoagulated blood using Lymphopaque
(specific gravity 1.086 g ml—1, 350 mOsmol). The blood sample
(± 7 ml) was layered on 3 ml of Lymphopaque using 10-ml
LeucoSep tubes and centrifuged at 800 ´ g at room temperature
for 20 min. The interface containing the PBM cells was collected,
diluted with phosphate-buffered saline (PBS; 9.2 mM disodium
hydrogen phosphate, 1.3 mM sodium dihydrogen phosphate and
140 mM sodium chloride, pH 7.4) to a final volume of approxi-
mately 15 ml and centrifuged at 800 g for 8 min. To lyse the
erythrocytes, the pellet was resuspended in 5 ml ice-cold ammo-
nium chloride solution (155 mM ammonium chloride, 10 mM
potassium bicarbonate and 0.1 mM EDTA) and kept on ice for
5 min. After the addition of 10 ml ice-cold PBS, the solution was
centrifuged at 250 g at 4°C for 10 min. This step was repeated
twice to remove the platelets. The resulting pellet was resus-
pended in 3 ml of PBS and an aliquot was used for cell counting.
The purity of the PBM cells was assessed by morphological
examination of the cell suspension on a cytospin preparation
stained with Jenner—Giemsa. The remaining suspension was
centrifuged at 11 000 g at 4°C for 10 s. The supernatant was
discarded and the pellet was frozen in liquid nitrogen and stored
at —80°C until further analysis.
Purification of blood cells
Buffy coats (leucocyte-enriched fractions) from 500 ml of human
blood were obtained after informed consent from healthy donors
without an allergic history. The buffy coat (about 50 ml) was
diluted to 200 ml with PBS containing 13 mM trisodium citrate and
centrifuged over Percoll (specific gravity 1.077 g cm—3,
290 mOsmol), as described previously (De Korte et al, 1985;
De Boer and Roos, 1986). The neutrophilic and eosinophilic gran-
ulocytes were purified from an aliquot of the pellet by lysing the
erythrocytes with an isotonic ammonium chloride solution at 4°C.
The solution was centrifuged at 420 g at 4°C for 5 min, and the
resulting pellet was washed twice with PBS. The final cell prepa-
ration contained >95% neutrophils and <5% eosinophils (De Boer
and Roos, 1986). Pure ￿packed￿ erythrocytes were obtained by
washing the cell pellet of the Percoll separation three times with
0.9% (w/v) sodium chloride (1700 g for 10 min), with successive
removal of the upper layer of the resulting cell pellet containing
the contaminating leucocytes (granulocytes).
The platelets were purified from the interphase of the Percoll
separation by elutriation centrifugation between 2100 and 1800 g,
essentially as described previously (De Boer and Roos, 1986). In
addition, platelets were purified from the supernatant (platelet-rich
plasma) obtained after centrifugation of EDTA-anticoagulated
blood over Lymphopaque. The fractions containing the platelets
were further purified by removing contaminating erythrocytes and
leucocytes with centrifugation (400 g for 5 min). The supernatant
containing pure platelets (>99%) was collected and the platelets
were obtained by centrifugation (1600 g for 10 min).
The mononuclear leucocytes were purified from the interphase
of the Percoll separation by elutriation centrifugation, essentially
as described previously (De Boer and Roos, 1986), with minor
modifications. During the elutriation procedure, lymphocytes were
obtained between 1450 and 1000 g and monocytes between 850
and 150 g. The fraction containing the monocytes (>85%) was
incubated in a culture flask at 37°C for 0.5 h in RPMI culture
medium supplemented with 10% FCS. After washing the flask
with PBS, the attached monocytes were removed with 5 mM
EDTA in PBS. The final preparation of cells contained more than
99% monocytes. The lymphocytes obtained with the elutriation
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procedure were collected and the remaining erythrocytes were
lysed with isotonic ammonium chloride solution at 4°C. The solu-
tion was centrifuged at 400 g at 4°C for 5 min, and the resulting
pellet was washed twice with PBS. The final cell preparation
contained >99% lymphocytes.
Determination of the DPD activity
The activity of DPD was determined in a reaction mixture
containing 35 mM potassium phosphate (pH 7.4), 2.5 mM magne-
sium chloride, 1 mM dithiothreitol, 250 mM NADPH and 25 mM
[2-14C]thymine (Van Kuilenburg et al, 1996). Separation of radio-
labelled thymine from radiolabelled dihydrothymine was
performed isocratically [50 mM sodium dihydrogen phosphate
(pH 4.5) at a flow rate of 2 ml min—1] by reversed-phase HPLC on
a Supelcosil LC-18-S column (250 ´ 4.6 mm, 5-mm particle size)
with online detection of the radioactivity, as described previously
(Van Kuilenburg et al, 1996). Protein concentrations were deter-
mined with a copper reduction method using bicinchoninic acid,
essentially as described by Smith et al (1985).
Statistical analysis
The differences between the mean activities of DPD between
various blood cells were analysed with the two sample t-test. In
case of unequal variances, as indicated by Levene￿s test for
equality of variances, the log-transformed data were used or the
original data were tested with the non-parametric Mann—Whitney
test. The correlations between the activity of DPD and the
percentage of monocytes or lymphocytes and between the DPD
activity in monocytes and lymphocytes were studied by determina-
tion of Pearson￿s correlation coefficients and linear regression. The
level of significance was set a priori at P † 0.05. Analyses were
performed with the Statistical Package for the Social Sciences
(SPSS, Chicago, IL, USA).
RESULTS
To investigate the activity of DPD in human blood cells, we puri-
fied the various blood cell types with density centrifugation and
elutriation centrifugation. Figure 1 shows that the highest specific
activity of DPD was observed in monocytes, followed by lympho-
cytes, granulocytes and platelets. In erythrocytes, only a very low
activity of DPD could be detected (Table 1), which might have been
caused by the presence of some residual granulocytes (<0.2%). The
mean specific activity of DPD in monocytes proved to be 2.5 times
higher than the mean specific activity of DPD in lymphocytes
(Table 1). The mean activity of DPD in lymphocytes was approxi-
mately 2.5 times higher than the mean specific activity of DPD in
granulocytes. A small but significant difference in activity of DPD
was observed between granulocytes and platelets (P = 0.02). The
activity of DPD in PBM cells obtained by density centrifugation
proved to be intermediate compared with the DPD activity
observed in monocytes and lymphocytes. This observation is in line
with the fact that a differential count showed that the PBM cells
contained on average 23 ± 12% monocytes (range 5—52%).
Figure 2 shows the DPD activity in the various blood cell types
and PBM cells when expressed per million cells instead of per
milligram of protein (Figure 1). In this way, the mean specific
activity of DPD in monocytes proved to be 5.4 times higher than
the mean specific activity of DPD in lymphocytes (Table 2).
Furthermore, a comparable mean activity of DPD was observed in
lymphocytes and granulocytes. These phenomena are in accor-
dance with the observation that monocytes and granulocytes
contain approximately twice as much protein per million cells
compared with that found in lymphocytes (De Korte et al, 1985).
Investigation of the intradonor activity of DPD showed that a
highly significant correlation (r = 0.81, P = 0.001) exists between
the activity of DPD detected in lymphocytes and that measured in
monocytes (Figure 3). Apparently, a high activity of DPD in
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Figure 1 The DPD activity (nmol mg–1 protein h–1) in various blood cells of
healthy volunteers. The activity of DPD was determined in the various blood
cell types isolated by density centrifugation and elutriation. The number of
samples analysed is given in parentheses. The mean activities of DPD in the
blood cells are indicated by solid lines. The significance of the difference
between the mean activities of DPD in various blood cells was analysed
statistically and is indicated by their P-values
Table 1 The DPD activity in various blood cells of healthy volunteers
Parameters PBM cells Monocytes Lymphocytes Granulocytes Platelets Erythrocytes
(n = 17) (n = 12) (n = 16) (n = 7) (n = 22) (n = 5)
Mean activity 9.6 13.7 5.6 2.2 1.7 0.0044
(nmol mg–1 h–1)
s.d. 3.7 5.5 1.5 0.5 0.6 0.0020
s.e. 0.9 1.6 0.4 0.2 0.1 0.0009
Range 3.4–18.4 6.0–26.6 3.8–9.6 1.5–2.8 0.8–3.6 0.0018–0.0070
95% CI for the mean 7.7–11.5 10.2–17.2 4.8–6.4 1.8–2.7 1.4–1.9 0.0020–0.0069
Median 9.4 13.7 5.3 2.1 1.5 0.0050
The activity of DPD (nmol mg–1 h–1) was determined in the various blood cell types isolated by density centrifugation and elutriation. The number of samples
analysed is given in parentheses. CI, confidence interval.Dihydropyrimidine dehydrogenase activity in human blood cells 623
British Journal of Cancer (1999) 79(3/4), 620–626 © Cancer Research Campaign 1999
lymphocytes is paralleled by a high activity of DPD in monocytes
and vice versa.
Because our results demonstrate that the highest activity of
DPD is present in monocytes and the fact that PBM cells purified
with density centrifugation over Percoll contain a substantial
amount of monocytes, we investigated whether a correlation exists
between the DPD activity measured in PBM cells and the
percentage of monocytes and lymphocytes in PBM cell suspen-
sions. Figure 4 shows that a positive correlation exists between the
DPD activity of PBM cells obtained from tumour patients and the
percentage of monocytes (Figure 4A). Consequently, a negative
correlation was observed between the DPD activity in PBM cells
and the percentage of lymphocytes (Figure 4B). In an analogous
way, a positive correlation was observed between the DPD activity
of PBM cells obtained from healthy volunteers (r = 0.83,
P = 0.0002) and the percentage of monocytes. Interestingly, the
mean percentage of monocytes in the PBM cells obtained from
tumour patients (45 ± 24%) proved to be significantly higher than
that observed in PBM cells obtained from healthy volunteers
(23 ± 12%, P = 0.01). Analysis by linear regression showed that
the DPD activity in PBM cells of tumour patients can be described
by the following equations:
DPDactivity (nmol mg—1 h—1) = A (% monocytes) + C (1)
A = 0.092 nmol mg—1 h—1; 95% confidence interval,
0.04—0.14 nmol mg—1 h—1
C = 5.1 nmol mg—1 h—1; 95% confidence interval, 2.5—
7.6 nmol mg—1 h—1
P =0.03 P <0.001
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Figure 2 The DPD activity [nmol (106 cells)–1 h–1] in various blood cells of
healthy volunteers. The activity of DPD was determined in the various blood
cell types isolated by density centrifugation and elutriation. The number of
samples analysed is given in parentheses. The mean activities of DPD in the
blood cells are indicated by solid lines. The significance of the difference
between the mean activities of DPD in various blood cells was analysed
statistically and is indicated by their P-values
Figure 3 Correlation between the intradonor activity of DPD in monocytes
and lymphocytes. The correlation between the activity of DPD in monocytes
and lymphocytes was studied by determination of the Pearsons correlation
coefficient and linear regression
Table 2 The DPD activity in various blood cells of healthy volunteers
Parameters PBM cells Monocytes Lymphocytes Granulocytes Platelets Erythrocytes
(n = 15) (n = 9) (n = 11) (n = 6) (n = 15) (n = 5)
Mean activity 0.36 0.55 0.10 0.09 2.3 ´ 10–3 0.11 ´ 10–3
s.d. 0.08 0.22 0.03 0.02 0.65 ´ 10–3 0.052 ´ 10–3
s.e. 0.02 0.07 0.01 0.01 0.17 ´ 10–3 0.023 ´ 10–3
Range 0.24–0.48 0.19–0.85 0.05–0.15 0.05–0.11 1.4–3.5 ´ 10–3 0.05–0.18 ´ 10–3
95% CI for the mean 0.32–0.40 0.38–0.72 0.08–0.12 0.07–0.11 1.9–2.7 ´ 10–3 0.04–0.17 ´ 10–3
Median 0.38 0.62 0.10 0.10 2.1 ´ 10–3 0.11 ´ 10–3
The activity of DPD (nmol (106 cells–1) h–1) was determined in the various blood cell types isolated by density centrifugation and elutriation. The number of
samples analysed is given in parentheses. CI, confidence interval.
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Figure 4 Relationship between the activity of DPD measured in PBM cells
obtained from tumour patients and the percentage of monocytes (A) and
lymphocytes (B). Granulocytes were normally not present in the fraction
containing the PBM cells (< 2%). However, the fraction containing the PBM
cells of one individual contained up to 16% of granulocytes. The correlations
between the activity of DPD and the percentage of monocytes and
lymphocytes were studied by determination of the Pearsons correlation
coefficients and linear regression624 ABP Van Kuilenburg
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DPDactivity (nmol mg—1 h—1) = A (% lymphocytes) + C (2)
A = —0.099 nmol mg—1 h—1; 95% confidence interval,
(—0.16)—(—0.04) nmol mg—1 h—1
C = 14.5 nmol mg—1 h—1; 95% confidence interval, 11.1—
17.8 nmol mg—1 h—1
In both equations, the values that can be calculated for the DPD
activity in pure preparations of lymphocytes or monocytes are in
accordance with those obtained with elutriation centrifugation
(Table 1).
DISCUSSION
In this study, we investigated the activity of DPD in various blood
cell types purified with density gradient centrifugation followed by
elutriation, and showed that a profound activity of DPD can be
detected in all types of blood cells except red blood cells. The pres-
ence of DPD activity in platelets is in line with the observation of
Pero et al (1984), who showed that thymine was degraded in the
presence of platelets. Until now, the highest specific activity of
DPD had been found in lymphocytes (Naguib et al, 1985).
However, our results clearly demonstrate that the specific activity
of DPD in monocytes even exceeds that of lymphocytes. From our
results, it can also be estimated that in peripheral blood the
majority of the DPD activity is located in platelets.
In two cancer patients suffering from a partial DPD deficiency,
the decreased activity of DPD in PBM cells was paralleled by a
decreased activity of DPD in the liver as well (Lu et al, 1993).
Therefore, it has been suggested that the activity of DPD in PBM
cells could be used as a marker for DPD activity in general (Lu et
al, 1993). Our results demonstrated that indeed a strong correlation
(r2 = 0.66) appears to exist between the activity of DPD in lympho-
cytes and in monocytes. Although the activity of DPD can be
detected in a variety of human tissues, one should bear in mind that
the catabolism of 5-FU does mainly take place in the liver (Naguib
et al, 1985; Ho et al, 1986). In this respect, it has been shown that
only a modest correlation exists between the DPD activity
measured in PBM cells and that of liver (Chazal et al, 1996).
Furthermore, only a very weak correlation (r2 = 0.09) exists
between the clearance of 5FU and the activity of DPD in PBM
cells (Etienne et al, 1994). As a consequence, these authors stated
that the optimization of the doses of 5FU to be administered to the
patients based on their individual DPD activities in PBM cells
cannot be recommended. However, a conceivable possibility
might be that the large inter-patient variation in the activity of
DPD might have been caused by the presence of varying amounts
of monocytes, thus hampering the establishment of a more
profound correlation between the clearance of 5-FU and the
activity of DPD.
The significantly increased percentage of monocytes in the
PBM cells from tumour patients compared with that observed in
PBM cells from healthy volunteers is in line with recent findings
of Kaffenberger et al (1995). They observed before the start of the
treatment of patients with advanced squamous cell carcinomas of
the head and neck a reduction of T- and B-lymphocytes to 64% and
81%, respectively, compared with the means of healthy volunteers,
whereas the percentage of monocytes was not influenced
(Kaffenberger et al, 1995). Furthermore, during the treatment of
these patients with radiotherapy or chemotherapy, a major shift
was observed among the mononuclear cells to the monocytic
lineage (Kaffenberger et al, 1995). Thus, a relative enrichment in
the percentage of monocytes was observed in the PBM cells of
these patients. In this respect, it is interesting to note that the mean
activity of DPD as measured in total PBM cells obtained from
cancer patients has been reported to be slightly higher than that
from healthy volunteers (Lu et al, 1993; Etienne et al, 1994;
Milano and Etienne, 1994a, b).
In general, dose escalation of cytotoxic chemotherapy has been
limited primarily by neutropenia and thrombocytopenia. Because
the major toxic risks in the past have been related to neutropenic
infections and haemorrhage, the cycle length is frequently deter-
mined by the time necessary to achieve safe values for neutrophils
and platelets. It has been shown that patients with breast cancer
undergoing adjuvant chemotherapy possessed decreased concen-
trations of peripheral blood lymphocytes (Strender et al, 1981).
Furthermore, it has been shown that the time between successive
cycles of (radio)chemotherapy was adequate for a sufficient
recovery of granulocytes, platelets and monocytes, whereas the
lymphocyte populations did not recover before the administration
of the next cycle of therapy (Mackall et al, 1994; Kaffenberger et
al, 1995). Because we demonstrated that the activity of DPD is not
restricted to lymphocytes but is also present in monocytes, it
might, therefore, at least partly explain the large interpatient varia-
tion in DPD activity measured in PBM cells, as well as for the
substantial intrapatient variation in case the activity of DPD was
measured between different chemotherapy cycles (Fleming et al,
1992; Etienne et al, 1994). It should be stressed that the occurrence
of monocytosis is not a very rare phenomenon and might be more
frequently encountered than generally anticipated (Maldonado and
Hanlon, 1965).
The presence of substantial amounts of monocytes in PBM cells
might also contribute to the large six- to ninefold range in activity
of DPD emerging from population studies of DPD in normal
subjects and cancer patients with coefficient of variations (CV)
ranging from 34% to 38% (Fleming et al, 1993; Lu et al, 1993;
Etienne et al, 1994; McMurrough and McLeod, 1996). Subjects
with high levels of monocytes will automatically segregate to the
upper part of the distribution curve, whereas those with merely
lymphocytes will tend to segregate in the lower part of the distrib-
ution profile.
The analysis of the DPD activity in 124 healthy subjects (Lu et
al, 1993) and 185 cancer patients (Etienne et al, 1994) did not
reveal patients with a complete deficiency of DPD. Recently,
however, a number of cancer patients have been found with low
activities of DPD experiencing increased toxicities, including
death, after 5-FU treatment (Lu et al, 1993). Based on the upper
threshold value of the activity of DPD which is indicative of an
increased risk for developing severe 5-FU-related toxicity, it has
been estimated that approximately 3% of a group of cancer
patients are located below this threshold (Etienne et al, 1994).
Although it has been suggested that these patients are heterozy-
gous for a DPD mutation, heterozygosity for a mutated DPD allele
has so far only been shown in two cancer patients (Wei et al, 1996;
Van Kuilenburg et al, 1997a, 1998a). It is likely that the category
of tumour patients with a DPD activity below the threshold value
also include those patients with PBM cells containing a high
percentage of lymphocytes. Therefore, the measurement of the
activity in PBM cells might hinder the detection of patients with a
partial DPD deficiency.
Initial studies by Harris et al (1990) demonstrated a profound
circadian rhythm in the activity of DPD, which was inversely
related to the plasma concentrations of 5-FU in patients treatedwith continuous infusion of 5FU. Recently, however, we and
others failed to demonstrate a clear circadian rhythm of DPD in
healthy volunteers and cancer patients (Grem et al, 1997; Van
Kuilenburg et al, 1998c). A point of concern might be the different
sleep—wake schedules and the disturbed sleep pattern, which might
be a potential source of variability (Diasio et al, 1995; Grem et al,
1997). In this respect, it is noteworthy that a significant circadian
rhythm has been demonstrated for all subsets of PBM cells, with a
suppressing effect of sleep on the number of circulating monocytes
and lymphocytes compared with sustained wakefulness (Haus,
1992; Born et al, 1997). A slightly different pattern was observed
for monocytes and lymphocytes as reflected by differences in the
calculated acrophase (time of the peak of the fitted curve). Because
Grem et al (1997) expressed the activity of DPD per million cells,
with the mean DPD activity in monocytes being approximately
five times that of lymphocytes, small differences in the percentage
of monocytes might have hampered the detection of a small but
consistent circadian pattern.
In summary, we have shown that a profound activity of DPD
can be detected in all types of blood cells except red blood cells,
with the highest activity of DPD being found in monocytes.
Furthermore, we have established a profound relationship between
the percentage of monocytes of the PBM cells and the DPD
activity, thus introducing a large inter- and intrapatient variability
in the activity of DPD and hindering the detection of patients with
a partial DPD deficiency.
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